102 results on '"Rumbaugh G"'
Search Results
2. Endogenous Syngap1 alpha splice forms promote cognitive function and seizure protection
- Author
-
Kilinc M., Arora V., Creson T.K., Rojas C., Le A.A., Lauterborn J., Wilkinson B., Hartel N., Graham N., Reich A., Gou G., Araki Y., Bayés À., Coba M., Lynch G., Miller C.A., and Rumbaugh G.
- Subjects
guanosine triphosphatase activating protein ,cognition ,seizure ,Syngap1 protein, mouse ,Mice ,synapse ,ras GTPase-Activating Proteins ,Seizures ,physiology ,Mutation ,Synapses ,isoprotein ,Animals ,Protein Isoforms ,animal ,genetics ,metabolism ,mouse - Abstract
Loss-of-function variants in SYNGAP1 cause a developmental encephalopathy defined by cognitive impairment, autistic features, and epilepsy. SYNGAP1 splicing leads to expression of distinct functional protein isoforms. Splicing imparts multiple cellular functions of SynGAP proteins through coding of distinct C-terminal motifs. However, it remains unknown how these different splice sequences function in vivo to regulate neuronal function and behavior. Reduced expression of SynGAP-a1/2 C-terminal splice variants in mice caused severe phenotypes, including reduced survival, impaired learning, and reduced seizure latency. In contrast, upregulation of a1/2 expression improved learning and increased seizure latency. Mice expressing a1-specific mutations, which disrupted SynGAP cellular functions without altering protein expression, promoted seizure, disrupted synapse plasticity, and impaired learning. These findings demonstrate that endogenous SynGAP isoforms with a1/2 spliced sequences promote cognitive function and impart seizure protection. Regulation of SynGAP-aexpression or function may be a viable therapeutic strategy to broadly improve cognitive function and mitigate seizure. © 2022, Kilinc et al.
- Published
- 2022
3. MicroRNA regulation of persistent stress-enhanced memory (vol 25, pg 965, 2019)
- Author
-
Sillivan, S.E., Jamieson, S., Nijs, L. de, Jones, M., Snijders, C., Klengel, T., Joseph, N.F., Krauskopf, J., Kleinjans, J., Vinkers, C.H., Boks, M.P.M., Geuze, E., Vermetten, E., Berretta, S., Ressler, K.J., Rutten, B.P.F., Rumbaugh, G., and Miller, C.A.
- Subjects
Hardware_INTEGRATEDCIRCUITS ,ComputerApplications_COMPUTERSINOTHERSYSTEMS ,Hardware_PERFORMANCEANDRELIABILITY ,GeneralLiterature_MISCELLANEOUS - Abstract
A correction to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
4. PERSISTING CORTICAL DNA METHYLATION FOLLOWING HIPPOCAMPUS-DEPENDENT LEARNING: YIC01-02
- Author
-
Miller, C. A., Rumbaugh, G., and Sweatt, J. D.
- Published
- 2009
5. PRO56 UNDERSTANDING DISEASE AND BURDEN IN SYNGAP1-RELATED NON-SYNDROMIC INTELLECTUAL DISABILITY (NSID) PATIENTS USING A PATIENT REGISTRY DATABASE
- Author
-
Weldon, M., primary, Holder, J., additional, Rumbaugh, G., additional, Smith-Hicks, C., additional, Boulanger, V., additional, Seebald, A., additional, Rossov, S., additional, Milligan, K., additional, and Radtchenko, J., additional
- Published
- 2019
- Full Text
- View/download PDF
6. Supplementary Material for: Improved Scalability of Neuron-Based Phenotypic Screening Assays for Therapeutic Discovery in Neuropsychiatric Disorders
- Author
-
Spicer, T.P., Hubbs, C., Vaissiere, T., Collia, D., Rojas, C., Kilinc, M., Vick, K., Madoux, F., Baillargeon, P., Shumate, J., Martemyanov, K.A., Page, D.T., Puthanveettil, S., Hodder, P., Davis, R., Miller, C.A., Scampavia, L., and Rumbaugh, G.
- Abstract
There is a pressing need to improve approaches for drug discovery related to neuropsychiatric disorders (NSDs). Therapeutic discovery in neuropsychiatric disorders would benefit from screening assays that can measure changes in complex phenotypes linked to disease mechanisms. However, traditional assays that track complex neuronal phenotypes, such as neuronal connectivity, exhibit poor scalability and are not compatible with high-throughput screening (HTS) procedures. Therefore, we created a neuronal phenotypic assay platform that focused on improving the scalability and affordability of neuron-based assays capable of tracking disease-relevant phenotypes. First, using inexpensive laboratory-level automation, we industrialized primary neuronal culture production, which enabled the creation of scalable assays within functioning neural networks. We then developed a panel of phenotypic assays based on culturing of primary neurons from genetically modified mice expressing HTS-compatible reporters that capture disease-relevant phenotypes. We demonstrated that a library of 1,280 compounds was quickly screened against both assays using only a few litters of mice in a typical academic laboratory setting. Finally, we implemented one assay in a fully automated high-throughput academic screening facility, illustrating the scalability of assays designed using this platform. These methodological improvements simplify the creation of highly scalable neuron-based phenotypic assays designed to improve drug discovery in CNS disorders.
- Published
- 2017
- Full Text
- View/download PDF
7. Nonmuscle myosin IIB as a therapeutic target for the prevention of relapse to methamphetamine use
- Author
-
Young, E J, primary, Blouin, A M, additional, Briggs, S B, additional, Sillivan, S E, additional, Lin, L, additional, Cameron, M D, additional, Rumbaugh, G, additional, and Miller, C A, additional
- Published
- 2015
- Full Text
- View/download PDF
8. SYNGAP1 Links the Maturation Rate of Excitatory Synapses to the Duration of Critical-Period Synaptic Plasticity
- Author
-
Clement, J. P., primary, Ozkan, E. D., additional, Aceti, M., additional, Miller, C. A., additional, and Rumbaugh, G., additional
- Published
- 2013
- Full Text
- View/download PDF
9. MicroRNA-182 Regulates Amygdala-Dependent Memory Formation
- Author
-
Griggs, E. M., primary, Young, E. J., additional, Rumbaugh, G., additional, and Miller, C. A., additional
- Published
- 2013
- Full Text
- View/download PDF
10. Regulation of Synapse Structure and Function by Distinct Myosin II Motors
- Author
-
Rubio, M. D., primary, Johnson, R., additional, Miller, C. A., additional, Huganir, R. L., additional, and Rumbaugh, G., additional
- Published
- 2011
- Full Text
- View/download PDF
11. Synapses Fight Over Glutamate Receptor 1
- Author
-
Rumbaugh, G., primary
- Published
- 2005
- Full Text
- View/download PDF
12. Distinct effect of pregnenolone sulfate on NMDA receptor subtypes
- Author
-
Ceccon, M., Rumbaugh, G., and Vicini, S.
- Published
- 2001
- Full Text
- View/download PDF
13. Haploinsufficiency of Syngap1 in striatal indirect pathway neurons alters motor and goal-directed behaviors in mice.
- Author
-
Haetzel LM, Iafrati J, Cording KR, Farhan M, Noveir SD, Rumbaugh G, and Bateup HS
- Abstract
SYNGAP1 is a high-confidence autism spectrum disorder (ASD) risk gene and mutations in SYNGAP1 lead to a neurodevelopmental disorder (NDD) that presents with epilepsy, ASD, motor developmental delay, and intellectual disability. SYNGAP1 codes for Ras/Rap GTP-ase activating protein SynGAP (SynGAP). In mice, SynGAP is located in the postsynaptic density of glutamatergic synapses and regulates glutamate receptor trafficking in an activity-dependent manner. In addition to forebrain glutamatergic neurons, Syngap1 is highly expressed in the striatum, although the functions of SynGAP in the striatum have not been extensively studied. Here we show that Syngap1 is expressed in both direct and indirect pathway striatal projection neurons (dSPNs and iSPNs) in mice of both sexes. In a mouse model of Syngap1 haploinsufficiency, dendritic spine density, morphology, and intrinsic excitability are altered primarily in iSPNs, but not dSPNs. At the behavioral level, SynGAP reduction alters striatal-dependent motor learning and goal-directed behavior. Several behavioral phenotypes are reproduced by iSPN-specific Syngap1 reduction and, in turn, prevented by iSPN-specific Syngap1 rescue. These results establish the importance of SynGAP to striatal neuron function and pinpoint the indirect pathway as a key circuit in the neurobiology of SYNGAP1 -related NDD. Significance statement SYNGAP1 mutations cause a neurodevelopmental disorder presenting with intellectual disability, motor problems, epilepsy, autism spectrum disorder, and a constellation of other behavioral and psychiatric conditions. SynGAP protein is highly expressed in the striatum but its functions in this brain region have not yet been explored. This study shows that loss of one copy of the Syngap1 gene from striatal indirect, but not direct, pathway neurons alters synaptic properties, cellular excitability, motor behaviors, and goal-directed responding in mice. This work provides a new perspective on the functions of SynGAP and suggests that altered activity in striatal circuits may be an important driver of the motor and learning alterations in people with SYNGAP1 disorder., (Copyright © 2024 Haetzel et al.)
- Published
- 2024
- Full Text
- View/download PDF
14. Syngap1 Promotes Cognitive Function through Regulation of Cortical Sensorimotor Dynamics.
- Author
-
Vaissiere T, Michaelson SD, Creson T, Goins J, Fürth D, Balazsfi D, Rojas C, Golovin R, Meletis K, Miller CA, O'Connor D, Fontolan L, and Rumbaugh G
- Abstract
Perception, a cognitive construct, emerges through sensorimotor integration (SMI). The genetic mechanisms that shape SMI required for perception are unknown. Here, we demonstrate in mice that expression of the autism/intellectual disability gene, Syngap1 , in cortical excitatory neurons is required for formation of somatomotor networks that promote SMI-mediated perception. Cortical Syngap1 expression was necessary and sufficient for setting tactile sensitivity, sustaining tactile object exploration, and promoting tactile learning. Mice with deficient Syngap1 expression exhibited impaired neural dynamics induced by exploratory touches within a cortical-thalamic network known to promote attention and perception. Disrupted neuronal dynamics were associated with circuit-specific long-range synaptic connectivity abnormalities. Our data support a model where autonomous Syngap1 expression in cortical excitatory neurons promotes cognitive abilities through assembly of circuits that integrate temporally-overlapping sensory and motor signals, a process that promotes perception and attention. These data provide systems-level insights into the robust association between Syngap1 expression and cognitive ability.
- Published
- 2024
- Full Text
- View/download PDF
15. MT-125 Inhibits Non-Muscle Myosin IIA and IIB, Synergizes with Oncogenic Kinase Inhibitors, and Prolongs Survival in Glioblastoma.
- Author
-
Kenchappa R, Radnai L, Young EJ, Zarco N, Lin L, Dovas A, Meyer CT, Haddock A, Hall A, Canoll P, Cameron MD, Nagaiah NK, Rumbaugh G, Griffin PR, Kamenecka TM, Miller CA, and Rosenfeld SS
- Abstract
We have identified a NMIIA and IIB-specific small molecule inhibitor, MT-125, and have studied its effects in GBM. MT-125 has high brain penetrance and retention and an excellent safety profile; blocks GBM invasion and cytokinesis, consistent with the known roles of NMII; and prolongs survival as a single agent in murine GBM models. MT-125 increases signaling along both the PDGFR- and MAPK-driven pathways through a mechanism that involves the upregulation of reactive oxygen species, and it synergizes with FDA-approved PDGFR and mTOR inhibitors in vitro . Combining MT-125 with sunitinib, a PDGFR inhibitor, or paxalisib, a combined PI3 Kinase/mTOR inhibitor significantly improves survival in orthotopic GBM models over either drug alone, and in the case of sunitinib, markedly prolongs survival in ∼40% of mice. Our results provide a powerful rationale for developing NMII targeting strategies to treat cancer and demonstrate that MT-125 has strong clinical potential for the treatment of GBM., Highlights: MT-125 is a highly specific small molecule inhibitor of non-muscle myosin IIA and IIB, is well-tolerated, and achieves therapeutic concentrations in the brain with systemic dosing.Treating preclinical models of glioblastoma with MT-125 produces durable improvements in survival.MT-125 stimulates PDGFR- and MAPK-driven signaling in glioblastoma and increases dependency on these pathways.Combining MT-125 with an FDA-approved PDGFR inhibitor in a mouse GBM model synergizes to improve median survival over either drug alone, and produces tumor free, prolonged survival in over 40% of mice.
- Published
- 2024
- Full Text
- View/download PDF
16. Basolateral amygdala corticotropin releasing factor receptor 2 interacts with nonmuscle myosin II to destabilize memory in males.
- Author
-
Hafenbreidel M, Pandey S, Briggs SB, Arza M, Bonthu S, Fisher C, Tiller A, Hall AB, Reed S, Mayorga N, Lin L, Khan S, Cameron MD, Rumbaugh G, and Miller CA
- Subjects
- Animals, Female, Male, Mice, Actins, Myosin Type II metabolism, Basolateral Nuclear Complex metabolism, Cocaine pharmacology, Methamphetamine pharmacology, Receptors, Corticotropin-Releasing Hormone metabolism
- Abstract
Preclinical studies show that inhibiting the actin motor ATPase nonmuscle myosin II (NMII) with blebbistatin (Blebb) in the basolateral amgydala (BLA) depolymerizes actin, resulting in an immediate, retrieval-independent disruption of methamphetamine (METH)-associated memory in male and female adult and adolescent rodents. The effect is highly selective, as NMII inhibition has no effect in other relevant brain regions (e.g., dorsal hippocampus [dPHC], nucleus accumbens [NAc]), nor does it interfere with associations for other aversive or appetitive stimuli, including cocaine (COC). To understand the mechanisms responsible for drug specific selectivity we began by investigating, in male mice, the pharmacokinetic differences in METH and COC brain exposure . Replicating METH's longer half-life with COC did not render the COC association susceptible to disruption by NMII inhibition. Therefore, we next assessed transcriptional differences. Comparative RNA-seq profiling in the BLA, dHPC and NAc following METH or COC conditioning identified crhr2, which encodes the corticotropin releasing factor receptor 2 (CRF2), as uniquely upregulated by METH in the BLA. CRF2 antagonism with Astressin-2B (AS2B) had no effect on METH-associated memory after consolidation, allowing for determination of CRF2 influences on NMII-based susceptibility. Pretreatment with AS2B prevented the ability of Blebb to disrupt an established METH-associated memory. Alternatively, combining CRF2 overexpression and agonist treatment, urocortin 3 (UCN3), in the BLA during conditioning rendered COC-associated memory susceptible to disruption by NMII inhibition, mimicking the Blebb-induced, retrieval-independent memory disruption seen with METH. These results suggest that BLA CRF2 receptor activation during memory formation in male mice can prevent stabilization of the actin-myosin cytoskeleton supporting the memory, rendering it vulnerable to disruption by NMII inhibition. CRF2 represents an interesting target for BLA-dependent memory destabilization via downstream effects on NMII., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
17. Non-synaptic function of the autism spectrum disorder-associated gene SYNGAP1 in cortical neurogenesis.
- Author
-
Birtele M, Del Dosso A, Xu T, Nguyen T, Wilkinson B, Hosseini N, Nguyen S, Urenda JP, Knight G, Rojas C, Flores I, Atamian A, Moore R, Sharma R, Pirrotte P, Ashton RS, Huang EJ, Rumbaugh G, Coba MP, and Quadrato G
- Subjects
- Animals, Mice, Humans, ras GTPase-Activating Proteins genetics, Phenotype, Neurogenesis genetics, Autism Spectrum Disorder genetics, Neurodevelopmental Disorders genetics
- Abstract
Genes involved in synaptic function are enriched among those with autism spectrum disorder (ASD)-associated rare genetic variants. Dysregulated cortical neurogenesis has been implicated as a convergent mechanism in ASD pathophysiology, yet it remains unknown how 'synaptic' ASD risk genes contribute to these phenotypes, which arise before synaptogenesis. Here, we show that the synaptic Ras GTPase-activating (RASGAP) protein 1 (SYNGAP1, a top ASD risk gene) is expressed within the apical domain of human radial glia cells (hRGCs). In a human cortical organoid model of SYNGAP1 haploinsufficiency, we find dysregulated cytoskeletal dynamics that impair the scaffolding and division plane of hRGCs, resulting in disrupted lamination and accelerated maturation of cortical projection neurons. Additionally, we confirmed an imbalance in the ratio of progenitors to neurons in a mouse model of Syngap1 haploinsufficiency. Thus, SYNGAP1-related brain disorders may arise through non-synaptic mechanisms, highlighting the need to study genes associated with neurodevelopmental disorders (NDDs) in diverse human cell types and developmental stages., (© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
18. Vagal sensory neurons mediate the Bezold-Jarisch reflex and induce syncope.
- Author
-
Lovelace JW, Ma J, Yadav S, Chhabria K, Shen H, Pang Z, Qi T, Sehgal R, Zhang Y, Bali T, Vaissiere T, Tan S, Liu Y, Rumbaugh G, Ye L, Kleinfeld D, Stringer C, and Augustine V
- Subjects
- Humans, Area Postrema, Bradycardia complications, Bradycardia physiopathology, Cardiac Output, Low complications, Cardiac Output, Low physiopathology, Echocardiography, Heart Rate, Hypotension complications, Hypotension physiopathology, Laser-Doppler Flowmetry, Nerve Net, Single-Cell Gene Expression Analysis, Heart physiology, Reflex physiology, Sensory Receptor Cells physiology, Syncope complications, Syncope etiology, Vagus Nerve cytology, Vagus Nerve physiology
- Abstract
Visceral sensory pathways mediate homeostatic reflexes, the dysfunction of which leads to many neurological disorders
1 . The Bezold-Jarisch reflex (BJR), first described2,3 in 1867, is a cardioinhibitory reflex that is speculated to be mediated by vagal sensory neurons (VSNs) that also triggers syncope. However, the molecular identity, anatomical organization, physiological characteristics and behavioural influence of cardiac VSNs remain mostly unknown. Here we leveraged single-cell RNA-sequencing data and HYBRiD tissue clearing4 to show that VSNs that express neuropeptide Y receptor Y2 (NPY2R) predominately connect the heart ventricular wall to the area postrema. Optogenetic activation of NPY2R VSNs elicits the classic triad of BJR responses-hypotension, bradycardia and suppressed respiration-and causes an animal to faint. Photostimulation during high-resolution echocardiography and laser Doppler flowmetry with behavioural observation revealed a range of phenotypes reflected in clinical syncope, including reduced cardiac output, cerebral hypoperfusion, pupil dilation and eye-roll. Large-scale Neuropixels brain recordings and machine-learning-based modelling showed that this manipulation causes the suppression of activity across a large distributed neuronal population that is not explained by changes in spontaneous behavioural movements. Additionally, bidirectional manipulation of the periventricular zone had a push-pull effect, with inhibition leading to longer syncope periods and activation inducing arousal. Finally, ablating NPY2R VSNs specifically abolished the BJR. Combined, these results demonstrate a genetically defined cardiac reflex that recapitulates characteristics of human syncope at physiological, behavioural and neural network levels., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
19. Basolateral Amygdala Corticotrophin Releasing Factor Receptor 2 Interacts with Nonmuscle Myosin II to Destabilize Memory.
- Author
-
Hafenbreidel M, Briggs SB, Arza M, Bonthu S, Fisher C, Tiller A, Hall AB, Reed S, Mayorga N, Lin L, Khan S, Cameron MD, Rumbaugh G, and Miller CA
- Abstract
Inhibiting the actin motor ATPase nonmuscle myosin II (NMII) with blebbistatin (Blebb) in the basolateral amgydala (BLA) depolymerizes actin, resulting in an immediate, retrieval-independent disruption of methamphetamine (METH)-associated memory. The effect is highly selective, as NMII inhibition has no effect in other relevant brain regions (e.g. dorsal hippocampus [dPHC], nucleus accumbens [NAc]), nor does it interfere with associations for other aversive or appetitive stimuli, including cocaine (COC). To investigate a potential source of this specificity, pharmacokinetic differences in METH and COC brain exposure were examined. Replicating METH's longer half-life with COC did not render the COC association susceptible to disruption by NMII inhibition. Therefore, transcriptional differences were next assessed. Comparative RNA-seq profiling in the BLA, dHPC and NAc following METH or COC conditioning identified crhr2 , which encodes the corticotrophin releasing factor receptor 2 (CRF2), as uniquely upregulated by METH in the BLA. CRF2 antagonism with Astressin-2B (AS2B) had no effect on METH-associated memory after consolidation, allowing for determination of CRF2 influences on NMII-based susceptibility after METH conditioning. Pretreatment with AS2B occluded the ability of Blebb to disrupt an established METH-associated memory. Alternatively, the Blebb-induced, retrieval-independent memory disruption seen with METH was mimicked for COC when combined with CRF2 overexpression in the BLA and its ligand, UCN3 during conditioning. These results indicate that BLA CRF2 receptor activation during learning can prevent stabilization of the actin-myosin cytoskeleton supporting the memory, rendering it vulnerable to disruption via NMII inhibition. CRF2 represents an interesting target for BLA-dependent memory destabilization via downstream effects on NMII., Competing Interests: Competing Interests Authors have nothing to disclose.
- Published
- 2023
- Full Text
- View/download PDF
20. Endogenous Syngap1 alpha splice forms promote cognitive function and seizure protection.
- Author
-
Kilinc M, Arora V, Creson TK, Rojas C, Le AA, Lauterborn J, Wilkinson B, Hartel N, Graham N, Reich A, Gou G, Araki Y, Bayés À, Coba M, Lynch G, Miller CA, and Rumbaugh G
- Subjects
- Animals, Cognition, Mice, Mutation, Protein Isoforms genetics, Synapses physiology, Seizures genetics, ras GTPase-Activating Proteins genetics, ras GTPase-Activating Proteins metabolism
- Abstract
Loss-of-function variants in SYNGAP1 cause a developmental encephalopathy defined by cognitive impairment, autistic features, and epilepsy. SYNGAP1 splicing leads to expression of distinct functional protein isoforms. Splicing imparts multiple cellular functions of SynGAP proteins through coding of distinct C-terminal motifs. However, it remains unknown how these different splice sequences function in vivo to regulate neuronal function and behavior. Reduced expression of SynGAP-α1/2 C-terminal splice variants in mice caused severe phenotypes, including reduced survival, impaired learning, and reduced seizure latency. In contrast, upregulation of α1/2 expression improved learning and increased seizure latency. Mice expressing α1-specific mutations, which disrupted SynGAP cellular functions without altering protein expression, promoted seizure, disrupted synapse plasticity, and impaired learning. These findings demonstrate that endogenous SynGAP isoforms with α1/2 spliced sequences promote cognitive function and impart seizure protection. Regulation of SynGAP-αexpression or function may be a viable therapeutic strategy to broadly improve cognitive function and mitigate seizure., Competing Interests: MK, VA, TC, CR, AL, JL, BW, NH, NG, AR, GG, YA, ÀB, MC, GL, CM, GR No competing interests declared, (© 2022, Kilinc et al.)
- Published
- 2022
- Full Text
- View/download PDF
21. Discovery of Selective Inhibitors for In Vitro and In Vivo Interrogation of Skeletal Myosin II.
- Author
-
Radnai L, Surman M, Hafenbreidel M, Young EJ, Stremel RF, Lin L, Bdiri B, Pasetto P, Jin X, Geedy M, Partridge JR, Patel A, Conlon M, Sellers JR, Cameron MD, Rumbaugh G, Griffin PR, Kamenecka TM, and Miller CA
- Subjects
- Animals, Mice, Molecular Structure, Muscle, Skeletal metabolism, Myosin Type II metabolism, Myosin Type II toxicity, Heterocyclic Compounds, 4 or More Rings chemistry, Myosin Type II antagonists & inhibitors
- Abstract
Myosin IIs, actin-based motors that utilize the chemical energy of adenosine 5'-triphosphate (ATP) to generate force, have potential as therapeutic targets. Their heavy chains differentiate the family into muscle (skeletal [SkMII], cardiac, smooth) and nonmuscle myosin IIs. Despite the therapeutic potential for muscle disorders, SkMII-specific inhibitors have not been reported and characterized. Here, we present the discovery, synthesis, and characterization of "skeletostatins," novel derivatives of the pan-myosin II inhibitor blebbistatin, with selectivity 40- to 170-fold for SkMII over all other myosin II family members. In addition, the skeletostatins bear improved potency, solubility, and photostability, without cytotoxicity. Based on its optimal in vitro profile, MT-134's in vivo tolerability, efficacy, and pharmacokinetics were determined. MT-134 was well-tolerated in mice, impaired motor performance, and had excellent exposure in muscles. Skeletostatins are useful probes for basic research and a strong starting point for drug development.
- Published
- 2021
- Full Text
- View/download PDF
22. Syngap1 regulates experience-dependent cortical ensemble plasticity by promoting in vivo excitatory synapse strengthening.
- Author
-
Llamosas N, Michaelson SD, Vaissiere T, Rojas C, Miller CA, and Rumbaugh G
- Subjects
- Animals, Cerebral Cortex physiology, Epigenesis, Genetic, Female, Humans, Male, Mice, Patch-Clamp Techniques, Vibrissae, ras GTPase-Activating Proteins genetics, Autistic Disorder genetics, Neuronal Plasticity genetics, Neurons metabolism, Synapses physiology, Touch, ras GTPase-Activating Proteins metabolism
- Abstract
A significant proportion of autism risk genes regulate synapse function, including plasticity, which is believed to contribute to behavioral abnormalities. However, it remains unclear how impaired synapse plasticity contributes to network-level processes linked to adaptive behaviors, such as experience-dependent ensemble plasticity. We found that Syngap1 , a major autism risk gene, promoted measures of experience-dependent excitatory synapse strengthening in the mouse cortex, including spike-timing-dependent glutamatergic synaptic potentiation and presynaptic bouton formation. Synaptic depression and bouton elimination were normal in Syngap1 mice. Within cortical networks, Syngap1 promoted experience-dependent increases in somatic neural activity in weakly active neurons. In contrast, plastic changes to highly active neurons from the same ensemble that paradoxically weaken with experience were unaffected. Thus, experience-dependent excitatory synapse strengthening mediated by Syngap1 shapes neuron-specific plasticity within cortical ensembles. We propose that other genes regulate neuron-specific weakening within ensembles, and together, these processes function to redistribute activity within cortical networks during experience., Competing Interests: The authors declare no competing interest.
- Published
- 2021
- Full Text
- View/download PDF
23. SynGAP is expressed in the murine suprachiasmatic nucleus and regulates circadian-gated locomotor activity and light-entrainment capacity.
- Author
-
Aten S, Kalidindi A, Yoon H, Rumbaugh G, Hoyt KR, and Obrietan K
- Subjects
- Animals, Locomotion, Mice, Mice, Inbred C57BL, Suprachiasmatic Nucleus, ras GTPase-Activating Proteins, Circadian Clocks, Circadian Rhythm
- Abstract
The suprachiasmatic nucleus (SCN) of the hypothalamus functions as the master circadian clock. The phasing of the SCN oscillator is locked to the daily solar cycle, and an intracellular signaling cassette from the small GTPase Ras to the p44/42 mitogen-activated protein kinase (ERK/MAPK) pathway is central to this entrainment process. Here, we analyzed the expression and function of SynGAP-a GTPase-activating protein that serves as a negative regulator of Ras signaling-within the murine SCN. Using a combination of immunohistochemical and Western blotting approaches, we show that SynGAP is broadly expressed throughout the SCN. In addition, temporal profiling assays revealed that SynGAP expression is regulated over the circadian cycle, with peak expression occurring during the circadian night. Further, time-of-day-gated expression of SynGAP was not observed in clock arrhythmic BMAL1 null mice, indicating that the daily oscillation in SynGAP is driven by the inherent circadian timing mechanism. We also show that SynGAP phosphorylation at serine 1138-an event that has been found to modulate its functional efficacy-is regulated by clock time and is responsive to photic input. Finally, circadian phenotypic analysis of Syngap1 heterozygous mice revealed enhanced locomotor activity, increased sensitivity to light-evoked clock entrainment, and elevated levels of light-evoked MAPK activity, which is consistent with the role of SynGAP as a negative regulator of MAPK signaling. These findings reveal that SynGAP functions as a modulator of SCN clock entrainment, an effect that may contribute to sleep and circadian abnormalities observed in patients with SYNGAP1 gene mutations., (© 2020 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
24. SYNGAP1 Controls the Maturation of Dendrites, Synaptic Function, and Network Activity in Developing Human Neurons.
- Author
-
Llamosas N, Arora V, Vij R, Kilinc M, Bijoch L, Rojas C, Reich A, Sridharan B, Willems E, Piper DR, Scampavia L, Spicer TP, Miller CA, Holder JL, and Rumbaugh G
- Subjects
- CRISPR-Cas Systems, Cell Differentiation genetics, Cell Size, Cells, Cultured, Excitatory Postsynaptic Potentials genetics, Female, Gene Deletion, Humans, Neurodevelopmental Disorders genetics, Pluripotent Stem Cells, Dendrites physiology, Nerve Net physiology, Nervous System growth & development, Synapses physiology, ras GTPase-Activating Proteins genetics, ras GTPase-Activating Proteins physiology
- Abstract
SYNGAP1 is a major genetic risk factor for global developmental delay, autism spectrum disorder, and epileptic encephalopathy. De novo loss-of-function variants in this gene cause a neurodevelopmental disorder defined by cognitive impairment, social-communication disorder, and early-onset seizures. Cell biological studies in mouse and rat neurons have shown that Syngap1 regulates developing excitatory synapse structure and function, with loss-of-function variants driving formation of larger dendritic spines and stronger glutamatergic transmission. However, studies to date have been limited to mouse and rat neurons. Therefore, it remains unknown how SYNGAP1 loss of function impacts the development and function of human neurons. To address this, we used CRISPR/Cas9 technology to ablate SYNGAP1 protein expression in neurons derived from a commercially available induced pluripotent stem cell line (hiPSC) obtained from a human female donor. Reducing SynGAP protein expression in developing hiPSC-derived neurons enhanced dendritic morphogenesis, leading to larger neurons compared with those derived from isogenic controls. Consistent with larger dendritic fields, we also observed a greater number of morphologically defined excitatory synapses in cultures containing these neurons. Moreover, neurons with reduced SynGAP protein had stronger excitatory synapses and expressed synaptic activity earlier in development. Finally, distributed network spiking activity appeared earlier, was substantially elevated, and exhibited greater bursting behavior in SYNGAP1 null neurons. We conclude that SYNGAP1 regulates the postmitotic maturation of human neurons made from hiPSCs, which influences how activity develops within nascent neural networks. Alterations to this fundamental neurodevelopmental process may contribute to the etiology of SYNGAP1 -related disorders. SIGNIFICANCE STATEMENT SYNGAP1 is a major genetic risk factor for global developmental delay, autism spectrum disorder, and epileptic encephalopathy. While this gene is well studied in rodent neurons, its function in human neurons remains unknown. We used CRISPR/Cas9 technology to disrupt SYNGAP1 protein expression in neurons derived from an induced pluripotent stem cell line. We found that induced neurons lacking SynGAP expression exhibited accelerated dendritic morphogenesis, increased accumulation of postsynaptic markers, early expression of synapse activity, enhanced excitatory synaptic strength, and early onset of neural network activity. We conclude that SYNGAP1 regulates the postmitotic differentiation rate of developing human neurons and disrupting this process impacts the function of nascent neural networks. These altered developmental processes may contribute to the etiology of SYNGAP1 disorders., (Copyright © 2020 the authors.)
- Published
- 2020
- Full Text
- View/download PDF
25. A simple and robust cell-based assay for the discovery of novel cytokinesis inhibitors.
- Author
-
Radnai L, Stremel RF, Vaissiere T, Lin L, Cameron M, Martin WH, Rumbaugh G, Kamenecka TM, Griffin PR, and Miller CA
- Abstract
Cytokinesis is the last step of mitotic cell division that separates the cytoplasm of dividing cells. Small molecule inhibitors targeting either the elements of the regulatory pathways controlling cytokinesis, or the terminal effectors have been of interest as potential drug candidates for the treatment of various diseases. Here we present a detailed protocol for a cell-based cytokinesis assay that can be used for the discovery of novel cytokinesis inhibitors. The assay is performed in a 96-well plate format in 48 h. Living cells, nuclei and nuclei of dead cells are identified by a single staining step using three fluorescent dyes, followed by rapid live cell imaging. The primary signal is the nuclei-to-cell ratio (NCR). In the presence of cytokinesis inhibitors, this ratio increases over time, as the ratio of multinucleated cells increases in the population. The ratio of dead nuclei to total nuclei provides a simultaneous measure of cytotoxicity. A screening window coefficient ( Z `) of 0.65 indicates that the assay is suitable for screening purposes, as the positive and negative controls are well-separated. EC
50 values can be reliably determined in a single 96-well plate by using only six different compound concentrations, enabling the testing of 4 compounds per plate. An excellent test-retest reliability ( R2 = 0.998) was found for EC50 values covering a ~1500-fold range of potencies. Established small molecule inhibitors of cytokinesis operating via direct action on actin dynamics or nonmuscle myosin II are used to demonstrate the robustness, simplicity and flexibility of the assay., Competing Interests: Competing interests: The authors have declared that no competing interests exist., (© 2013-2020 The Journal of Biological Methods, All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
26. SynGAP splice variants display heterogeneous spatio-temporal expression and subcellular distribution in the developing mammalian brain.
- Author
-
Gou G, Roca-Fernandez A, Kilinc M, Serrano E, Reig-Viader R, Araki Y, Huganir RL, de Quintana-Schmidt C, Rumbaugh G, and Bayés À
- Subjects
- Animals, Cerebral Cortex growth & development, Cerebral Cortex metabolism, Computer Simulation, Gene Expression Regulation, Developmental genetics, Hippocampus growth & development, Hippocampus metabolism, Humans, Isomerism, Mice, Mice, Inbred C57BL, Protein Isoforms biosynthesis, Protein Isoforms genetics, Proteomics, Subcellular Fractions metabolism, ras GTPase-Activating Proteins biosynthesis, Brain growth & development, ras GTPase-Activating Proteins genetics
- Abstract
The SynGAP protein is a major regulator of synapse biology and neural circuit function. Genetic variants linked to epilepsy and intellectual disability disrupt synaptic function and neural excitability. SynGAP has been involved in multiple signaling pathways and can regulate small GTPases with very different roles. Yet, the molecular bases behind this pleiotropy are poorly understood. We hypothesize that different SynGAP isoforms will mediate different sets of functions and that deciphering their spatio-temporal expression and subcellular localization will accelerate understanding their multiple functions. Using isoform-specific antibodies recognizing SynGAP in mouse and human samples we found distinctive developmental expression patterns for all SynGAP isoforms in five mouse brain areas. Particularly noticeable was the delayed expression of SynGAP-α1 isoforms, which directly bind to postsynaptic density-95, in cortex and hippocampus during the first 2 weeks of postnatal development. Suggesting that during this period other isoforms would have a more prominent role. Furthermore, we observed subcellular localization differences between isoforms, particularly throughout postnatal development. Consistent with previous reports, SynGAP was enriched in the postsynaptic density in the mature forebrain. However, SynGAP was predominantly found in non-synaptic locations in a period of early postnatal development highly sensitive to SynGAP levels. While, α1 isoforms were always found enriched in the postsynaptic density, α2 isoforms changed from a non-synaptic to a mostly postsynaptic density localization with age and β isoforms were always found enriched in non-synaptic locations. The differential expression and subcellular distribution of SynGAP isoforms may contribute to isoform-specific regulation of small GTPases, explaining SynGAP pleiotropy., (© 2020 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.)
- Published
- 2020
- Full Text
- View/download PDF
27. Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing.
- Author
-
Chen JL, Zhang P, Abe M, Aikawa H, Zhang L, Frank AJ, Zembryski T, Hubbs C, Park H, Withka J, Steppan C, Rogers L, Cabral S, Pettersson M, Wager TT, Fountain MA, Rumbaugh G, Childs-Disney JL, and Disney MD
- Subjects
- HeLa Cells, Humans, Models, Molecular, Molecular Structure, RNA Splicing genetics, RNA, Messenger genetics, Small Molecule Libraries chemical synthesis, Small Molecule Libraries chemistry, Thermodynamics, tau Proteins genetics, RNA Splicing drug effects, RNA, Messenger antagonists & inhibitors, Small Molecule Libraries pharmacology, tau Proteins antagonists & inhibitors
- Abstract
Approximately 95% of human genes are alternatively spliced, and aberrant splicing events can cause disease. One pre-mRNA that is alternatively spliced and linked to neurodegenerative diseases is tau (microtubule-associated protein tau), which can cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) and can contribute to Alzheimer's disease. Here, we describe the design of structure-specific lead small molecules that directly target tau pre-mRNA from sequence. This was followed by hit expansion and analogue synthesis to further improve upon these initial lead molecules. The emergent compounds were assessed for functional activity in a battery of assays, including binding assays and an assay that mimics molecular recognition of tau pre-mRNA by a U1 small nuclear ribonucleoprotein (snRNP) splicing factor. Compounds that emerged from these studies had enhanced potency and selectivity for the target RNA relative to the initial hits, while also having significantly improved drug-like properties. The compounds are shown to directly target tau pre-mRNA in cells, via chemical cross-linking and isolation by pull-down target profiling, and to rescue disease-relevant splicing of tau pre-mRNA in a variety of cellular systems, including primary neurons. More broadly, this study shows that lead, structure-specific compounds can be designed from sequence and then further optimized for their physicochemical properties while at the same time enhancing their activity.
- Published
- 2020
- Full Text
- View/download PDF
28. Correction: MicroRNA regulation of persistent stress-enhanced memory.
- Author
-
Sillivan SE, Jamieson S, de Nijs L, Jones M, Snijders C, Klengel T, Joseph NF, Krauskopf J, Kleinjans J, Vinkers CH, Boks MPM, Geuze E, Vermetten E, Berretta S, Ressler KJ, Rutten BPF, Rumbaugh G, and Miller CA
- Abstract
A correction to this paper has been published and can be accessed via a link at the top of the paper.
- Published
- 2020
- Full Text
- View/download PDF
29. MicroRNA regulation of persistent stress-enhanced memory.
- Author
-
Sillivan SE, Jamieson S, de Nijs L, Jones M, Snijders C, Klengel T, Joseph NF, Krauskopf J, Kleinjans J, Vinkers CH, Boks MPM, Geuze E, Vermetten E, Berretta S, Ressler KJ, Rutten BPF, Rumbaugh G, and Miller CA
- Subjects
- Animals, Basolateral Nuclear Complex physiology, Female, Humans, Male, Mice, MicroRNAs analysis, MicroRNAs blood, Fear physiology, Memory physiology, MicroRNAs genetics
- Abstract
Disruption of persistent, stress-associated memories is relevant for treating posttraumatic stress disorder (PTSD) and related syndromes, which develop in a subset of individuals following a traumatic event. We previously developed a stress-enhanced fear learning (SEFL) paradigm in inbred mice that produces PTSD-like characteristics in a subset of mice, including persistently enhanced memory and heightened cFos in the basolateral amygdala complex (BLC) with retrieval of the remote (30-day-old) stress memory. Here, the contribution of BLC microRNAs (miRNAs) to stress-enhanced memory was investigated because of the molecular complexity they achieve through their ability to regulate multiple targets simultaneously. We performed small-RNA sequencing (smRNA-Seq) and quantitative proteomics on BLC tissue collected from mice 1 month after SEFL and identified persistently changed microRNAs, including mir-135b-5p, and proteins associated with PTSD-like heightened fear expression. Viral-mediated overexpression of mir-135b-5p in the BLC of stress-resilient animals enhanced remote fear memory expression and promoted spontaneous renewal 14 days after extinction. Conversely, inhibition of BLC mir-135b-5p in stress-susceptible animals had the opposite effect, promoting a resilient-like phenotype. mir-135b-5p is highly conserved across mammals and was detected in post mortem human amygdala, as well as human serum samples. The mir-135b passenger strand, mir-135b-3p, was significantly elevated in serum from PTSD military veterans, relative to combat-exposed control subjects. Thus, miR-135b-5p may be an important therapeutic target for dampening persistent, stress-enhanced memory and its passenger strand a potential biomarker for responsivity to a mir-135-based therapeutic.
- Published
- 2020
- Full Text
- View/download PDF
30. Methamphetamine Learning Induces Persistent and Selective Nonmuscle Myosin II-Dependent Spine Motility in the Basolateral Amygdala.
- Author
-
Young EJ, Lin H, Kamenecka TM, Rumbaugh G, and Miller CA
- Subjects
- Animals, Basolateral Nuclear Complex drug effects, Conditioning, Operant drug effects, Dendritic Spines drug effects, Female, Male, Mice, Neurons drug effects, Association Learning drug effects, Basolateral Nuclear Complex metabolism, Central Nervous System Stimulants pharmacology, Dendritic Spines metabolism, Methamphetamine pharmacology, Neurons metabolism, Nonmuscle Myosin Type IIB metabolism
- Abstract
Nonmuscle myosin II inhibition (NMIIi) in the basolateral amygdala (BLA), but not dorsal hippocampus (CA1), selectively disrupts memories associated with methamphetamine (METH) days after learning, without retrieval. However, the molecular mechanisms underlying this selective vulnerability remain poorly understood. A known function of NMII is to transiently activate synaptic actin dynamics with learning. Therefore, we hypothesized that METH-associated learning perpetuates NMII-driven actin dynamics in synapses, leading to an extended window of vulnerability for memory disruption. We used time-lapse two-photon imaging of dendritic spine motility in acutely prepared brain slices from female and male mice following METH-associated learning as a readout of actin-myosin dynamics. Spine motility was persistently increased in the BLA, but not in CA1. Consistent with the memory disrupting effect of intra-BLA NMII inhibition, METH-induced changes to BLA spine dynamics were reversed by a single systemic injection of an NMII inhibitor. Intra-CA1 NMII inhibition, on the other hand, did not disrupt METH-associated memory. Thus, we report identification of a previously unknown ability for spine actin dynamics to persist days after stimulation and that this is under the control of NMII. Further, these perpetual NMII-driven spine actin dynamics in BLA neurons may contribute to the unique susceptibility of METH-associated memories. SIGNIFICANCE STATEMENT There are no Food and Drug Administration-approved pharmacotherapies to prevent relapse to the use of stimulants, such as methamphetamine (METH). Environmental cues become associated with drug use, such that the memories can elicit strong motivation to seek the drug during abstinence. We previously reported that the storage of METH-associated memories is uniquely vulnerable to immediate, retrieval-independent, and lasting disruption by direct actin depolymerization or by inhibiting the actin driver nonmuscle myosin II (NMII) in the BLA or systemically. Here we report a potential structural mechanism responsible for the unique vulnerability of METH-associated memories and METH-seeking behavior to NMII inhibition within the BLA., (Copyright © 2020 the authors.)
- Published
- 2020
- Full Text
- View/download PDF
31. The sixth international RASopathies symposium: Precision medicine-From promise to practice.
- Author
-
Gripp KW, Schill L, Schoyer L, Stronach B, Bennett AM, Blaser S, Brown A, Burdine R, Burkitt-Wright E, Castel P, Darilek S, Dias A, Dyer T, Ellis M, Erickson G, Gelb BD, Green T, Gross A, Ho A, Holder JL Jr, Inoue SI, Jelin AC, Kennedy A, Klein R, Kontaridis MI, Magoulas P, McConnell DB, McCormick F, Neel BG, Prada CE, Rauen KA, Roberts A, Rodriguez-Viciana P, Rosen N, Rumbaugh G, Sablina A, Solman M, Tartaglia M, Thomas A, Timmer WC, Venkatachalam K, Walsh KS, Wolters PL, Yi JS, Zenker M, and Ratner N
- Subjects
- Genetic Diseases, Inborn pathology, Germ-Line Mutation genetics, Humans, Signal Transduction genetics, Genetic Diseases, Inborn genetics, Mitogen-Activated Protein Kinase Kinases genetics, ras Proteins genetics
- Abstract
The RASopathies are a group of genetic disorders that result from germline pathogenic variants affecting RAS-mitogen activated protein kinase (MAPK) pathway genes. RASopathies share RAS/MAPK pathway dysregulation and share phenotypic manifestations affecting numerous organ systems, causing lifelong and at times life-limiting medical complications. RASopathies may benefit from precision medicine approaches. For this reason, the Sixth International RASopathies Symposium focused on exploring precision medicine. This meeting brought together basic science researchers, clinicians, clinician scientists, patient advocates, and representatives from pharmaceutical companies and the National Institutes of Health. Novel RASopathy genes, variants, and animal models were discussed in the context of medication trials and drug development. Attempts to define and measure meaningful endpoints for treatment trials were discussed, as was drug availability to patients after trial completion., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
32. Social stress-potentiated methamphetamine seeking.
- Author
-
Blouin AM, Pisupati S, Hoffer CG, Hafenbreidel M, Jamieson SE, Rumbaugh G, and Miller CA
- Subjects
- Amygdala drug effects, Analysis of Variance, Animals, Baclofen pharmacology, Cerebral Cortex drug effects, Conditioning, Operant, Extinction, Psychological, GABA-A Receptor Agonists pharmacology, GABA-B Receptor Agonists pharmacology, Interpersonal Relations, Male, Motivation, Muscimol pharmacology, Nucleus Accumbens drug effects, Proto-Oncogene Proteins c-fos metabolism, Rats, Long-Evans, Rats, Sprague-Dawley, Reinforcement, Psychology, Self Administration, Central Nervous System Stimulants pharmacology, Drug-Seeking Behavior drug effects, Methamphetamine pharmacology, Social Behavior, Stress, Psychological physiopathology
- Abstract
Human studies of substance use disorder show that psychological stress and drug availability interact following rehabilitation, contributing to the high relapse potential. Social stressors trigger particularly strong motivation for drug, but how this affects neuronal function to increase relapse is unknown. Animal models, which allow for the dissection of neural mechanisms, primarily utilize physical stressors to trigger relapse. To recapitulate psychosocial post-rehabilitation challenges in animals, we developed a model of social stress-potentiated methamphetamine (METH) seeking. Rats receive a single social defeat (SD) session after completion of self-administration and extinction of lever pressing. While a reminder of the SD was insufficient to reinstate METH seeking on its own, rats that received a reminder of SD followed by a METH-priming injection displayed potentiated reinstatement over METH-priming alone. Examination of neuronal activation patterns of the METH-primed reinstatement session identified c-Fos-immunoreactivity in the basolateral amygdala (BLA) as correlated with SD score, a measure of defeat latency. Rapidly defeated rats showed potentiated METH-primed reinstatement and elevated BLA c-Fos compared with controls. Conversely, rats that were undefeated during the social stress did not show potentiated METH-primed reinstatement or elevated BLA c-Fos. Interestingly, inactivation of the BLA with baclofen/muscimol prior to the stress reminder and METH-priming generated a potentiation of METH seeking in the undefeated rats, suggesting the BLA may mediate resilience to the stressor. This model provides a tool for the further dissection of neural mechanisms mediating social stress-potentiated relapse and for the development of relapse-reducing therapeutics., (© 2018 Society for the Study of Addiction.)
- Published
- 2019
- Full Text
- View/download PDF
33. A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors.
- Author
-
Radnai L, Stremel RF, Sellers JR, Rumbaugh G, and Miller CA
- Subjects
- Adenosine Triphosphate metabolism, Animals, Hydrolysis, Lactic Acid analysis, Lactic Acid metabolism, Myosin Type II antagonists & inhibitors, Myosin Type II metabolism, NAD analysis, Oxidation-Reduction, Pyruvic Acid analysis, Pyruvic Acid metabolism, Adenosine Triphosphatases antagonists & inhibitors, Adenosine Triphosphatases metabolism, Enzyme Inhibitors pharmacology, High-Throughput Screening Assays methods, NAD metabolism
- Abstract
ATPase enzymes utilize the free energy stored in adenosine triphosphate to catalyze a wide variety of endergonic biochemical processes in vivo that would not occur spontaneously. These proteins are crucial for essentially all aspects of cellular life, including metabolism, cell division, responses to environmental changes and movement. The protocol presented here describes a nicotinamide adenine dinucleotide (NADH)-coupled ATPase assay that has been adapted to semi-high throughput screening of small molecule ATPase inhibitors. The assay has been applied to cardiac and skeletal muscle myosin II's, two actin-based molecular motor ATPases, as a proof of principle. The hydrolysis of ATP is coupled to the oxidation of NADH by enzymatic reactions in the assay. First, the ADP generated by the ATPase is regenerated to ATP by pyruvate kinase (PK). PK catalyzes the transition of phosphoenolpyruvate (PEP) to pyruvate in parallel. Subsequently, pyruvate is reduced to lactate by lactate dehydrogenase (LDH), which catalyzes the oxidation of NADH in parallel. Thus, the decrease in ATP concentration is directly correlated to the decrease in NADH concentration, which is followed by change to the intrinsic fluorescence of NADH. As long as PEP is available in the reaction system, the ADP concentration remains very low, avoiding inhibition of the ATPase enzyme by its own product. Moreover, the ATP concentration remains nearly constant, yielding linear time courses. The fluorescence is monitored continuously, which allows for easy estimation of the quality of data and helps to filter out potential artifacts (e.g., arising from compound precipitation or thermal changes).
- Published
- 2019
- Full Text
- View/download PDF
34. microRNA mir-598-3p mediates susceptibility to stress enhancement of remote fear memory.
- Author
-
Jones ME, Sillivan SE, Jamieson S, Rumbaugh G, and Miller CA
- Subjects
- Animals, Anxiety metabolism, Computational Biology, Extinction, Psychological physiology, Female, Male, Mice, Inbred C57BL, MicroRNAs metabolism, Signal Transduction, Basolateral Nuclear Complex metabolism, Fear physiology, Memory physiology, MicroRNAs physiology, Stress, Psychological metabolism
- Abstract
microRNAs (miRNAs) have emerged as potent regulators of learning, recent memory, and extinction. However, our understanding of miRNAs directly involved in regulating complex psychiatric conditions perpetuated by aberrant memory, such as in posttraumatic stress disorder (PTSD), remains limited. To begin to address the role of miRNAs in persistent memories, we performed small-RNA sequencing on basolateral amygdala (BLA) tissue and identified miRNAs altered by auditory fear conditioning (FC) one month after training. mir-598-3p, a highly conserved miRNA previously unstudied in the brain, was down-regulated in the BLA. Further decreasing BLA mir-598-3p levels did not increase strength of the remote fear memory. Given that stress is a critical component in PTSD, we next assessed the impact of stress and stress-enhanced fear learning (SEFL) on mir-598-3p levels, finding the miRNA is elevated in the BLA of male, but not female, mice susceptible to the effects of stress in SEFL. Accordingly, intra-BLA inhibition of mir-598-3p interfered with expression and extinction of the remote fear memory in male, but not female, mice. This effect could not be attributed to an anxiolytic effect of miRNA inhibition. Finally, bioinformatic analysis following quantitative proteomics on BLA tissue collected 30 d post-SEFL training identified putative mir-598-3p targets and related pathways mediating the differential susceptibility, with evidence for regulation of the actin cytoskeleton, the core mediator of structural plasticity. Taken together, the results suggest BLA mir-598-3p may be recruited by stress to mediate a critical switch from a salient remote fear memory to one that is enhanced and extinction-resistant., (© 2019 Jones et al.; Published by Cold Spring Harbor Laboratory Press.)
- Published
- 2019
- Full Text
- View/download PDF
35. A Simple Procedure for Creating Scalable Phenotypic Screening Assays in Human Neurons.
- Author
-
Sridharan B, Hubbs C, Llamosas N, Kilinc M, Singhera FU, Willems E, Piper DR, Scampavia L, Rumbaugh G, and Spicer TP
- Subjects
- Biological Assay methods, Cells, Cultured, Drug Discovery methods, Drug Evaluation, Preclinical methods, Humans, Induced Pluripotent Stem Cells cytology, Neuronal Outgrowth drug effects, Neuronal Outgrowth physiology, Neurons cytology, Phenotype, Reproducibility of Results, Cell Differentiation physiology, High-Throughput Screening Assays methods, Induced Pluripotent Stem Cells physiology, Neurons physiology
- Abstract
Neurons created from human induced pluripotent stem cells (hiPSCs) provide the capability of identifying biological mechanisms that underlie brain disorders. IPSC-derived human neurons, or iNs, hold promise for advancing precision medicine through drug screening, though it remains unclear to what extent iNs can support early-stage drug discovery efforts in industrial-scale screening centers. Despite several reported approaches to generate iNs from iPSCs, each suffer from technological limitations that challenge their scalability and reproducibility, both requirements for successful screening assays. We addressed these challenges by initially removing the roadblocks related to scaling of iNs for high throughput screening (HTS)-ready assays. We accomplished this by simplifying the production and plating of iNs and adapting them to a freezer-ready format. We then tested the performance of freezer-ready iNs in an HTS-amenable phenotypic assay that measured neurite outgrowth. This assay successfully identified small molecule inhibitors of neurite outgrowth. Importantly, we provide evidence that this scalable iN-based assay was both robust and highly reproducible across different laboratories. These streamlined approaches are compatible with any iPSC line that can produce iNs. Thus, our findings indicate that current methods for producing iPSCs are appropriate for large-scale drug-discovery campaigns (i.e. >10e
5 compounds) that read out simple neuronal phenotypes. However, due to the inherent limitations of currently available iN differentiation protocols, technological advances are required to achieve similar scalability for screens that require more complex phenotypes related to neuronal function.- Published
- 2019
- Full Text
- View/download PDF
36. Re-expression of SynGAP protein in adulthood improves translatable measures of brain function and behavior.
- Author
-
Creson TK, Rojas C, Hwaun E, Vaissiere T, Kilinc M, Jimenez-Gomez A, Holder JL Jr, Tang J, Colgin LL, Miller CA, and Rumbaugh G
- Subjects
- Action Potentials, Animals, Behavior, Animal, Electroencephalography, Female, Humans, Male, Memory, Mice, Mice, Mutant Strains, Seizures metabolism, Seizures physiopathology, Sleep, Wakefulness, Aging metabolism, Behavior, Brain metabolism, ras GTPase-Activating Proteins metabolism
- Abstract
It remains unclear to what extent neurodevelopmental disorder (NDD) risk genes retain functions into adulthood and how they may influence disease phenotypes. SYNGAP1 haploinsufficiency causes a severe NDD defined by autistic traits, cognitive impairment, and epilepsy. To determine if this gene retains therapeutically-relevant biological functions into adulthood, we performed a gene restoration technique in a mouse model for SYNGAP1 haploinsufficiency. Adult restoration of SynGAP protein improved behavioral and electrophysiological measures of memory and seizure. This included the elimination of interictal events that worsened during sleep. These events may be a biomarker for generalized cortical dysfunction in SYNGAP1 disorders because they also worsened during sleep in the human patient population. We conclude that SynGAP protein retains biological functions throughout adulthood and that non-developmental functions may contribute to disease phenotypes. Thus, treatments that target debilitating aspects of severe NDDs, such as medically-refractory seizures and cognitive impairment, may be effective in adult patients., Competing Interests: TC, CR, EH, TV, MK, AJ, JH, JT, CM, GR No competing interests declared, LC Reviewing editor, eLife, (© 2019, Creson et al.)
- Published
- 2019
- Full Text
- View/download PDF
37. Bioinformatic analysis of long-lasting transcriptional and translational changes in the basolateral amygdala following acute stress.
- Author
-
Sillivan SE, Jones ME, Jamieson S, Rumbaugh G, and Miller CA
- Subjects
- Amygdala metabolism, Animals, Computational Biology methods, Gene Expression, Male, Mice, Mice, Inbred C57BL, MicroRNAs genetics, MicroRNAs metabolism, Protein Biosynthesis genetics, Proteomics, Psychological Trauma genetics, RNA, Messenger genetics, Transcription, Genetic genetics, Basolateral Nuclear Complex metabolism, Stress, Psychological genetics, Stress, Psychological metabolism
- Abstract
Stress profoundly impacts the brain and increases the risk of developing a psychiatric disorder. The brain's response to stress is mediated by a number of pathways that affect gene expression and protein function throughout the cell. Understanding how stress achieves such dramatic effects on the brain requires an understanding of the brain's stress response pathways. The majority of studies focused on molecular changes have employed repeated or chronic stress paradigms to assess the long-term consequences of stress and have not taken an integrative genomic and/or proteomic approach. Here, we determined the lasting impact of a single stressful event (restraint) on the broad molecular profile of the basolateral amygdala complex (BLC), a key brain region mediating emotion, memory and stress. Molecular profiling performed thirty days post-restraint consisted of small RNA sequencing, RNA sequencing and quantitative mass spectrometry and identified long-lasting changes in microRNA (miRNA), messenger RNA (mRNA) and proteins. Alignment of the three datasets further delineated the regulation of stress-specific pathways which were validated by qPCR and Western Blot analysis. From this analysis, mir-29a-5p was identified as a putative regulator of stress-induced adaptations in the BLC. Further, a number of predicted mir-29a-5p targets are regulated at the mRNA and protein level. The concerted and long-lasting disruption of multiple molecular pathways in the amygdala by a single stress event is expected to be sufficient to alter behavioral responses to a wide array of future experiences, including exposure to additional stressors., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
38. SYNGAP1 heterozygosity disrupts sensory processing by reducing touch-related activity within somatosensory cortex circuits.
- Author
-
Michaelson SD, Ozkan ED, Aceti M, Maity S, Llamosas N, Weldon M, Mizrachi E, Vaissiere T, Gaffield MA, Christie JM, Holder JL Jr, Miller CA, and Rumbaugh G
- Subjects
- Animals, Cognition physiology, Female, Haploinsufficiency, Humans, Male, Mice, Neurons physiology, Patch-Clamp Techniques, Registries, Sensation Disorders physiopathology, Nerve Net physiopathology, Sensation Disorders genetics, Somatosensory Cortex physiopathology, Touch physiology, Touch Perception physiology, ras GTPase-Activating Proteins genetics
- Abstract
In addition to cognitive impairments, neurodevelopmental disorders often result in sensory processing deficits. However, the biological mechanisms that underlie impaired sensory processing associated with neurodevelopmental disorders are generally understudied and poorly understood. We found that SYNGAP1 haploinsufficiency in humans, which causes a sporadic neurodevelopmental disorder defined by cognitive impairment, autistic features, and epilepsy, also leads to deficits in tactile-related sensory processing. In vivo neurophysiological analysis in Syngap1 mouse models revealed that upper-lamina neurons in somatosensory cortex weakly encode information related to touch. This was caused by reduced synaptic connectivity and impaired intrinsic excitability within upper-lamina somatosensory cortex neurons. These results were unexpected, given that Syngap1 heterozygosity is known to cause circuit hyperexcitability in brain areas more directly linked to cognitive functions. Thus, Syngap1 heterozygosity causes a range of circuit-specific pathologies, including reduced activity within cortical neurons required for touch processing, which may contribute to sensory phenotypes observed in patients.
- Published
- 2018
- Full Text
- View/download PDF
39. Species-conserved SYNGAP1 phenotypes associated with neurodevelopmental disorders.
- Author
-
Kilinc M, Creson T, Rojas C, Aceti M, Ellegood J, Vaissiere T, Lerch JP, and Rumbaugh G
- Subjects
- Animals, Conserved Sequence, Humans, Loss of Function Mutation, Mice, Neurodevelopmental Disorders metabolism, Neurodevelopmental Disorders pathology, ras GTPase-Activating Proteins chemistry, ras GTPase-Activating Proteins metabolism, Neurodevelopmental Disorders genetics, Phenotype, ras GTPase-Activating Proteins genetics
- Abstract
SYNGAP1 loss-of-function variants are causally associated with intellectual disability, severe epilepsy, autism spectrum disorder and schizophrenia. While there are hundreds of genetic risk factors for neurodevelopmental disorders (NDDs), this gene is somewhat unique because of the frequency and penetrance of loss-of-function variants found in patients combined with the range of brain disorders associated with SYNGAP1 pathogenicity. These clinical findings indicate that SYNGAP1 regulates fundamental neurodevelopmental processes that are necessary for brain development. Here, we describe four phenotypic domains that are controlled by Syngap1 expression across vertebrate species. Two domains, the maturation of cognitive functions and maintenance of excitatory-inhibitory balance, are defined exclusively through a review of the current literature. Two additional domains are defined by integrating the current literature with new data indicating that SYNGAP1/Syngap1 regulates innate survival behaviors and brain structure. These four phenotypic domains are commonly disrupted in NDDs, suggesting that a deeper understanding of developmental Syngap1 functions will be generalizable to other NDDs of known or unknown etiology. Therefore, we discuss the known molecular and cellular functions of Syngap1 and consider how these functions may contribute to the emergence of disease-relevant phenotypes. Finally, we identify major unexplored areas of Syngap1 neurobiology and discuss how a deeper understanding of this gene may uncover general principles of NDD pathobiology., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
40. The role of nonmuscle myosin II in polydrug memories and memory reconsolidation.
- Author
-
Briggs SB, Hafenbreidel M, Young EJ, Rumbaugh G, and Miller CA
- Subjects
- Animals, Heterocyclic Compounds, 4 or More Rings administration & dosage, Male, Mice, Mice, Inbred C57BL, Central Nervous System Stimulants pharmacology, Conditioning, Classical drug effects, Heterocyclic Compounds, 4 or More Rings pharmacology, Memory Consolidation drug effects, Mental Recall drug effects, Methamphetamine analogs & derivatives, Methamphetamine pharmacology, Nicotine pharmacology, Nonmuscle Myosin Type IIA antagonists & inhibitors, Nonmuscle Myosin Type IIB antagonists & inhibitors, Peripheral Nervous System Agents pharmacology
- Abstract
Using pharmacologic and genetic approaches targeting actin or the actin-driving molecular motor, nonmuscle myosin II (NMII), we previously discovered an immediate, retrieval-independent, and long-lasting disruption of methamphetamine- (METH-) and amphetamine-associated memories. A single intrabasolateral amygdala complex infusion or systemic administration of the NMII inhibitor Blebbistatin (Blebb) is sufficient to produce this disruption, which is selective, having no retrieval-independent effect on memories for fear, food reward, cocaine, or morphine. However, it was unclear if Blebb treatment would disrupt memories of other stimulants and amphetamine class drugs, such as nicotine (NIC) or mephedrone (MEPH; bath salts). Moreover, many individuals abuse multiple drugs, but it was unknown if Blebb could disrupt polydrug memories, or if the inclusion of another substance would render Blebb no longer able to disrupt METH-associated memories. Therefore, the present study had two primary goals: (1) to determine the ability of Blebb to disrupt NIC- or MEPH-associated memories, and (2) to determine the ability of METH to modify other unconditioned stimulus (US) associations' susceptibility to Blebb. To this end, using the conditional place preference model, mice were conditioned to NIC and MEPH alone or METH in combination with NIC, morphine, or foot shock. We report that, unlike METH, there was no retrieval-independent effect of Blebb on NIC- or MEPH-associated memories. However, similar to cocaine, reconsolidation of the memory for both drugs was disrupted. Further, when combined with METH administration, NIC- and morphine-, but not fear-, associated memories were rendered susceptible to disruption by Blebb. Given the high rate of polydrug use and the resurgence of METH use, these results have important implications for the treatment of substance use disorder., (© 2018 Briggs et al.; Published by Cold Spring Harbor Laboratory Press.)
- Published
- 2018
- Full Text
- View/download PDF
41. Atypical Endocannabinoid Signaling Initiates a New Form of Memory-Related Plasticity at a Cortical Input to Hippocampus.
- Author
-
Wang W, Jia Y, Pham DT, Palmer LC, Jung KM, Cox CD, Rumbaugh G, Piomelli D, Gall CM, and Lynch G
- Subjects
- Animals, Enzyme Inhibitors pharmacology, GABA Agents pharmacology, Hippocampus cytology, Lipid Metabolism drug effects, Lipid Metabolism genetics, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Munc18 Proteins deficiency, Munc18 Proteins genetics, Neural Pathways drug effects, Neurons drug effects, Neurons physiology, Perceptual Disorders genetics, Perceptual Disorders pathology, Piperidines pharmacology, Pyrazoles pharmacology, Rats, Rats, Sprague-Dawley, Signal Transduction drug effects, Cerebral Cortex physiology, Endocannabinoids metabolism, Hippocampus physiology, Memory physiology, Neural Pathways physiology, Signal Transduction physiology
- Abstract
Endocannabinoids (ECBs) depress transmitter release at sites throughout the brain. Here, we describe another form of ECB signaling that triggers a novel form of long-term potentiation (LTP) localized to the lateral perforant path (LPP) which conveys semantic information from cortex to hippocampus. Two cannabinoid CB1 receptor (CB1R) signaling cascades were identified in hippocampus. The first is pregnenolone sensitive, targets vesicular protein Munc18-1 and depresses transmitter release; this cascade is engaged by CB1Rs in Schaffer-Commissural afferents to CA1 but not in the LPP, and it does not contribute to LTP. The second cascade is pregnenolone insensitive and LPP specific; it entails co-operative CB1R/β1-integrin signaling to effect synaptic potentiation via stable enhancement of transmitter release. The latter cascade is engaged during LPP-dependent learning. These results link atypical ECB signaling to the encoding of a fundamental component of episodic memory and suggest a novel route whereby endogenous and exogenous cannabinoids affect cognition.
- Published
- 2018
- Full Text
- View/download PDF
42. Publisher Correction: An interactive framework for whole-brain maps at cellular resolution.
- Author
-
Fürth D, Vaissière T, Tzortzi O, Xuan Y, Märtin A, Lazaridis I, Spigolon G, Fisone G, Tomer R, Deisseroth K, Carlén M, Miller CA, Rumbaugh G, and Meletis K
- Abstract
In the version of this article initially published online, Daniel Fürth was not listed as a corresponding author. The error has been corrected in the print, PDF and HTML versions of this article.
- Published
- 2018
- Full Text
- View/download PDF
43. The first international conference on SYNGAP1-related brain disorders: a stakeholder meeting of families, researchers, clinicians, and regulators.
- Author
-
Weldon M, Kilinc M, Lloyd Holder J Jr, and Rumbaugh G
- Subjects
- Animals, Caregivers, Disease Models, Animal, Haploinsufficiency, Humans, Stakeholder Participation, Translational Research, Biomedical, Brain physiopathology, Intellectual Disability genetics, Intellectual Disability physiopathology, ras GTPase-Activating Proteins genetics
- Abstract
Background: Pathologic mutations in SYNGAP1 cause a genetically defined form of intellectual disability (ID) with comorbid epilepsy and autistic features. While only recently discovered, pathogenicity of this gene is a relatively frequent genetic cause of classically undefined developmental delay that progresses to ID with commonly occurring comorbidities., Main Body: A meeting of 150 people was held that included affected individuals and their caregivers, clinicians that treat this and related brain disorders, neuroscientists that study SYNGAP1 biology or the function of related genes, and representatives from government agencies that fund science and approve new medical treatments. The meeting focused on developing a consensus among all stakeholders as to how best to achieve a more fundamental and profound understanding of SYNGAP1 biology and its role in human disease., Short Conclusion: From all of these proceedings, several areas of consensus emerged. The clinicians and geneticists agreed that the prevalence of epilepsy and sensory processing impairments in SYNGAP1-related brain disorders approached 100%. The neurobiologists agreed that more basic research is needed to better understand the molecular and cellular functions of the Syngap1 gene, which will lead to targets for therapeutic intervention. Finally, everyone agreed that there is a pressing need to form a robust patient registry as an initial step toward a prospective natural history study of patients with pathogenic SYNGAP1 variants.
- Published
- 2018
- Full Text
- View/download PDF
44. Improved Scalability of Neuron-Based Phenotypic Screening Assays for Therapeutic Discovery in Neuropsychiatric Disorders.
- Author
-
Spicer TP, Hubbs C, Vaissiere T, Collia D, Rojas C, Kilinc M, Vick K, Madoux F, Baillargeon P, Shumate J, Martemyanov KA, Page DT, Puthanveettil S, Hodder P, Davis R, Miller CA, Scampavia L, and Rumbaugh G
- Abstract
There is a pressing need to improve approaches for drug discovery related to neuropsychiatric disorders (NSDs). Therapeutic discovery in neuropsychiatric disorders would benefit from screening assays that can measure changes in complex phenotypes linked to disease mechanisms. However, traditional assays that track complex neuronal phenotypes, such as neuronal connectivity, exhibit poor scalability and are not compatible with high-throughput screening (HTS) procedures. Therefore, we created a neuronal phenotypic assay platform that focused on improving the scalability and affordability of neuron-based assays capable of tracking disease-relevant phenotypes. First, using inexpensive laboratory-level automation, we industrialized primary neuronal culture production, which enabled the creation of scalable assays within functioning neural networks. We then developed a panel of phenotypic assays based on culturing of primary neurons from genetically modified mice expressing HTS-compatible reporters that capture disease-relevant phenotypes. We demonstrated that a library of 1,280 compounds was quickly screened against both assays using only a few litters of mice in a typical academic laboratory setting. Finally, we implemented one assay in a fully automated high-throughput academic screening facility, illustrating the scalability of assays designed using this platform. These methodological improvements simplify the creation of highly scalable neuron-based phenotypic assays designed to improve drug discovery in CNS disorders.
- Published
- 2018
- Full Text
- View/download PDF
45. An interactive framework for whole-brain maps at cellular resolution.
- Author
-
Fürth D, Vaissière T, Tzortzi O, Xuan Y, Märtin A, Lazaridis I, Spigolon G, Fisone G, Tomer R, Deisseroth K, Carlén M, Miller CA, Rumbaugh G, and Meletis K
- Subjects
- Animals, Gene Expression Regulation genetics, Gene Expression Regulation physiology, Genes, Immediate-Early physiology, Glutamate Decarboxylase metabolism, Green Fluorescent Proteins genetics, Green Fluorescent Proteins metabolism, LIM-Homeodomain Proteins genetics, LIM-Homeodomain Proteins metabolism, Male, Mice, Transgenic, Motor Activity, Nerve Tissue Proteins genetics, Nerve Tissue Proteins metabolism, Neuropeptide Y metabolism, Parvalbumins metabolism, Transcription Factors genetics, Transcription Factors metabolism, Brain cytology, Brain Mapping, Nerve Net physiology, Neural Pathways physiology, Neurons physiology
- Abstract
To deconstruct the architecture and function of brain circuits, it is necessary to generate maps of neuronal connectivity and activity on a whole-brain scale. New methods now enable large-scale mapping of the mouse brain at cellular and subcellular resolution. We developed a framework to automatically annotate, analyze, visualize and easily share whole-brain data at cellular resolution, based on a scale-invariant, interactive mouse brain atlas. This framework enables connectivity and mapping projects in individual laboratories and across imaging platforms, as well as multiplexed quantitative information on the molecular identity of single neurons. As a proof of concept, we generated a comparative connectivity map of five major neuron types in the corticostriatal circuit, as well as an activity-based map to identify hubs mediating the behavioral effects of cocaine. Thus, this computational framework provides the necessary tools to generate brain maps that integrate data from connectivity, neuron identity and function.
- Published
- 2018
- Full Text
- View/download PDF
46. Susceptibility and Resilience to Posttraumatic Stress Disorder-like Behaviors in Inbred Mice.
- Author
-
Daws SE, Joseph NF, Jamieson S, King ML, Chévere-Torres I, Fuentes I, Shumyatsky GP, Brantley AF, Rumbaugh G, and Miller CA
- Subjects
- Animals, Basolateral Nuclear Complex metabolism, Behavior, Animal, Corticosterone blood, Disease Models, Animal, Female, Freezing Reaction, Cataleptic, Learning, Male, Memory, Mice, Inbred C57BL, Sex Factors, Transcriptome, Disease Susceptibility, Resilience, Psychological, Stress Disorders, Post-Traumatic pathology, Stress Disorders, Post-Traumatic physiopathology
- Abstract
Background: The limited neurobiological understanding of posttraumatic stress disorder (PTSD) has been partially attributed to the need for improved animal models. Stress-enhanced fear learning (SEFL) in rodents recapitulates many PTSD-associated behaviors, including stress-susceptible and stress-resilient subgroups in outbred rats. Identification of subgroups requires additional behavioral phenotyping, a confound to mechanistic studies., Methods: We employed a SEFL paradigm in inbred male and female C57BL/6 mice that combines acute stress with fear conditioning to precipitate traumatic-like memories. Extinction and long-term retention of extinction were examined after SEFL. Further characterization of SEFL effects on male mice was performed with additional behavioral tests, determination of regional activation by Fos immunofluorescence, and RNA sequencing of the basolateral amygdala., Results: Stressed animals displayed persistently elevated freezing during extinction. While more uniform in females, SEFL produced male subgroups with differential susceptibility that were identified without posttraining phenotyping. Additional phenotyping of male mice revealed PTSD-associated behaviors, including extinction-resistant fear memory, hyperarousal, generalization, and dysregulated corticosterone in stress-susceptible male mice. Altered Fos activation was also seen in the infralimbic cortex and basolateral amygdala of stress-susceptible male mice after remote memory retrieval. Key behavioral outcomes, including susceptibility, were replicated by two independent laboratories. RNA sequencing of the basolateral amygdala revealed transcriptional divergence between the male subgroups, including genes with reported polymorphic association to patients with PTSD., Conclusions: This SEFL model provides a tool for development of PTSD therapeutics that is compatible with the growing number of mouse-specific resources. Furthermore, use of an inbred strain allows for investigation into epigenetic mechanisms that are expected to critically regulate susceptibility and resilience., (Copyright © 2017 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
47. Nonmuscle myosin II inhibition disrupts methamphetamine-associated memory in females and adolescents.
- Author
-
Young EJ, Briggs SB, Rumbaugh G, and Miller CA
- Subjects
- Animals, Drug-Seeking Behavior drug effects, Female, Rats, Reward, Self Administration, Central Nervous System Stimulants pharmacology, Dendritic Spines drug effects, Heterocyclic Compounds, 4 or More Rings pharmacology, Memory drug effects, Methamphetamine pharmacology, Nonmuscle Myosin Type IIA antagonists & inhibitors, Nonmuscle Myosin Type IIB antagonists & inhibitors
- Abstract
Memories associated with drug use can trigger strong motivation for the drug, which increases relapse vulnerability in substance use disorder (SUD). Currently there are no treatments for relapse to abuse of psychostimulants, such as methamphetamine (METH). We previously reported that storage of memories associated with METH, but not those for fear or food reward, and the concomitant spine density increase are disrupted in a retrieval-independent manner by depolymerizing actin in the basolateral amygdala complex (BLC) of adult male rats and mice. Similar results are achieved in males through intra-BLC or systemic inhibition of nonmuscle myosin II (NMII), a molecular motor that directly drives actin polymerization. Given the substantial differences in physiology between genders, we sought to determine if this immediate and selective disruption of METH-associated memory extends to adult females. A single intra-BLC infusion of the NMII inhibitor Blebbistatin (Blebb) produced a long-lasting disruption of context-induced drug seeking for at least 30days in female rats that mirrored our prior results in males. Furthermore, a single systemic injection of Blebb prior to testing disrupted METH-associated memory and the concomitant increase in BLC spine density in females. Importantly, as in males, the same manipulation had no effect on an auditory fear memory or associated BLC spine density. In addition, we established that the NMII-based disruption of METH-associated memory extends to both male and female adolescents. These findings provide further support that small molecular inhibitors of NMII have strong therapeutic potential for the prevention of relapse to METH abuse triggered by associative memories., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
48. Memory disrupting effects of nonmuscle myosin II inhibition depend on the class of abused drug and brain region.
- Author
-
Briggs SB, Blouin AM, Young EJ, Rumbaugh G, and Miller CA
- Subjects
- Analysis of Variance, Anesthetics, Local administration & dosage, Anesthetics, Local pharmacology, Animals, Brain metabolism, Brain ultrastructure, Central Nervous System Stimulants administration & dosage, Central Nervous System Stimulants pharmacology, Cocaine administration & dosage, Cocaine pharmacology, Conditioning, Operant drug effects, Conditioning, Operant physiology, Dendritic Spines drug effects, Dendritic Spines ultrastructure, Green Fluorescent Proteins genetics, Green Fluorescent Proteins metabolism, Memory Disorders metabolism, Memory Disorders pathology, Methamphetamine administration & dosage, Mice, Mice, Inbred C57BL, Mice, Transgenic, Microinjections, Morphine Derivatives administration & dosage, Morphine Derivatives pharmacology, Brain drug effects, Heterocyclic Compounds, 4 or More Rings toxicity, Memory Disorders chemically induced, Mental Recall drug effects, Myosin Type II metabolism
- Abstract
Depolymerizing actin in the amygdala through nonmuscle myosin II inhibition (NMIIi) produces a selective, lasting, and retrieval-independent disruption of the storage of methamphetamine-associated memories. Here we report a similar disruption of memories associated with amphetamine, but not cocaine or morphine, by NMIIi. Reconsolidation appeared to be disrupted with cocaine. Unlike in the amygdala, methamphetamine-associated memory storage was not disrupted by NMIIi in the hippocampus, nucleus accumbens, or orbitofrontal cortex. NMIIi in the hippocampus did appear to disrupt reconsolidation. Identification of the unique mechanisms responsible for NMII-mediated, amygdala-dependent disruption of memory storage associated with the amphetamine class may enable induction of retrieval-independent vulnerability to other pathological memories., (© 2017 Briggs et al.; Published by Cold Spring Harbor Laboratory Press.)
- Published
- 2017
- Full Text
- View/download PDF
49. Prioritizing the development of mouse models for childhood brain disorders.
- Author
-
Ogden KK, Ozkan ED, and Rumbaugh G
- Subjects
- Animals, Humans, Mice, Mice, Knockout, Mutation, Phenotype, Research Design, Risk Factors, Brain Diseases genetics, Disease Models, Animal, Neurodevelopmental Disorders genetics, Synapses genetics
- Abstract
Mutations in hundreds of genes contribute to cognitive and behavioral dysfunction associated with developmental brain disorders (DBDs). Due to the sheer number of risk factors available for study combined with the cost of developing new animal models, it remains an open question how genes should be prioritized for in-depth neurobiological investigations. Recent reviews have argued that priority should be given to frequently mutated genes commonly found in sporadic DBD patients. Intrigued by this idea, we explored to what extent "high priority" risk factors have been studied in animals in an effort to assess their potential for generating valuable preclinical models capable of advancing the neurobiological understanding of DBDs. We found that in-depth whole animal studies are lacking for many high priority genes, with relatively few neurobiological studies performed in construct valid animal models aimed at understanding the pathological substrates associated with disease phenotypes. However, some high priority risk factors have been extensively studied in animal models and they have generated novel insights into DBD patho-neurobiology while also advancing early pre-clinical therapeutic treatment strategies. We suggest that prioritizing model development toward genes frequently mutated in non-specific DBD populations will accelerate the understanding of DBD patho-neurobiology and drive novel therapeutic strategies. This article is part of the Special Issue entitled 'Synaptopathy--from Biology to Therapy'., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
50. Pharmacological Selectivity Within Class I Histone Deacetylases Predicts Effects on Synaptic Function and Memory Rescue.
- Author
-
Rumbaugh G, Daws SE, Ozkan ED, Rojas CS, Hubbs CR, Aceti M, Kilgore M, Kudugunti S, Puthanveettil SV, Sweatt JD, Rusche J, and Miller CA
- Subjects
- Alzheimer Disease complications, Alzheimer Disease genetics, Amyloid beta-Protein Precursor genetics, Animals, Animals, Newborn, Cells, Cultured, Conditioning, Psychological drug effects, Disease Models, Animal, Fear drug effects, Gene Expression Profiling, Green Fluorescent Proteins genetics, Green Fluorescent Proteins metabolism, Histone Deacetylase Inhibitors pharmacology, Humans, Hydroxamic Acids therapeutic use, Memory Disorders etiology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Mutation genetics, Neurons drug effects, Neurons physiology, Presenilin-1 genetics, Synaptophysin genetics, Synaptophysin metabolism, Histone Deacetylase Inhibitors therapeutic use, Histone Deacetylases metabolism, Memory Disorders drug therapy, Memory Disorders pathology, Synapses drug effects
- Abstract
Histone deacetylases (HDACs) are promising therapeutic targets for neurological and psychiatric disorders that impact cognitive ability, but the relationship between various HDAC isoforms and cognitive improvement is poorly understood, particularly in mouse models of memory impairment. A goal shared by many is to develop HDAC inhibitors with increased isoform selectivity in order to reduce unwanted side effects, while retaining procognitive effects. However, studies addressing this tack at the molecular, cellular and behavioral level are limited. Therefore, we interrogated the biological effects of class I HDAC inhibitors with varying selectivity and assessed a subset of these compounds for their ability to regulate transcriptional activity, synaptic function and memory. The HDAC-1, -2, and -3 inhibitors, RGFP963 and RGFP968, were most effective at stimulating synaptogenesis, while the selective HDAC3 inhibitor, RGFP966, with known memory enhancing abilities, had minimal impact. Furthermore, RGFP963 increased hippocampal spine density, while HDAC3 inhibition was ineffective. Genome-wide gene expression analysis by RNA sequencing indicated that RGFP963 and RGFP966 induce largely distinct transcriptional profiles in the dorsal hippocampus of mature mice. The results of bioinformatic analyses were consistent with RGFP963 inducing a transcriptional program that enhances synaptic efficacy. Finally, RGFP963, but not RGFP966, rescued memory in a mouse model of Alzheimer's Disease. Together, these studies suggest that the specific memory promoting properties of class I HDAC inhibitors may depend on isoform selectivity and that certain pathological brain states may be more receptive to HDAC inhibitors that improve network function by enhancing synapse efficacy.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.